Amendments to the claims

1. (Currently Amended) A compound of formula (I) or a pharmaceutically acceptable salt thereof:



(I)

wherein:

R_1 is halogen, cyano, C_{1-6}alkyl, C_{3-7}cycloalkyl, C_{3-7}cycloalkyloxy, C_{1-6}alkoxy, C_{1-6}alkylthio, hydroxy, amino, mono- or di-C_{1-6}alkylamino, an N-linked 4 to 7 membered heterocyclic group, nitro, haloC_{1-6}alkyl, haloC_{1-6}alkoxy, aryl, -$COOR_3$, -COR_4, [(]wherein R_3 and R_4 are independently hydrogen or C_{1-6}alkyl[)] or -COR_5,[(]wherein R_5 is amino, mono- or di-C_{1-6}alkylamino or an N-linked 4 to 7 membered heterocyclic group[)];
p is 0, 1, ~~or~~ 2 or 3;
Q is a 6- membered aromatic group or a 6-membered heteroaromatic group;
A is -(CH_2-CH_2)-, -(CH=CH)-, or a group -(CHR_7)- wherein R_7 is hydrogen, halogen, hydroxy, cyano, nitro, C_{1-6}alkyl, C_{3-7}cycloalkyl, C_{3-7}cycloalkyloxy, haloC_{1-6}alkyl, C_{1-6}alkoxy, haloC_{1-6}alkoxy or C_{1-6}alkylthio;
R_2 is hydrogen, halogen, hydroxy, cyano, nitro, C_{1-6}alkyl, C_{1-6}alkanoyl, C_{3-7}cycloalkyl, C_{3-7}cycloalkyloxy, haloC_{1-6}alkyl, C_{1-6}alkoxy, haloC_{1-6}alkoxy, C_{1-6}alkylthio, amino, mono- or di-C_{1-6}alkylamino or an N-linked 4 to 7 membered heterocyclic group;
X is oxygen, sulfur, -CH_2- or NR_8 wherein R_8 is hydrogen or C_{1-6}alkyl;
Y is a single bond, -CH_2-, -(CH_2)$_2$- or -CH=CH-; and
Z is an optionally substituted N-linked heterocyclic group or a C-linked 4 to 7 membered heterocyclic group containing at least one nitrogen, or Z is –NR_9R_{10} wherein R_9 and R_{10} are independently hydrogen or C_{1-6}alkyl.

2. (Original) A compound as claimed in claim 1, wherein when R_7 is hydrogen.

3. (Currently Amended) A compound as claimed in claim 1 ~~or claim 2~~, wherein A is CH_2-.

4. (Currently Amended) A compound as claimed in ~~any of claims 1-3~~ claim 1, wherein Q is phenyl.

5. (Currently Amended) A compound as claimed in ~~any of claims 1-4~~ claim 1, wherein p is 1, 2 or 3, and R_1 is/are halogen ~~(particularly chloro or fluoro)~~, C_{1-6}alkyl ~~(particularly methyl)~~ or CF_3.

6. (Currently Amended) A compound as claimed in ~~any of claims 1-5~~ claim 1, wherein when R_1 is attached at the position marked below with an asterisk, R_1 is fluoro:



7. (Currently Amended) A compound as claimed in ~~any of claims 1-6~~ claim 1, wherein when Q is phenyl and p is 1, R_1 is attached at the position marked below with an asterisk:



8. (Currently Amended) A compound as claimed in ~~any of claims 1-7~~ claim 1, wherein when Q is phenyl and p is 2 or 3, R_1 is attached at two or more of the positions marked below



with arrows:

9. (Currently Amended) A compound as claimed in ~~any of claims 1-8~~ claim 1, wherein R_2 is C_{1-6}alkoxy~~, particularly methoxy~~.

10. (Currently Amended) A compound as claimed in ~~any of claims 1-9~~ claim 1, wherein X is oxygen.

11. (Currently Amended) A compound as claimed in ~~any of claims 1-10~~ claim 1, wherein Y is $-CH_2-$.

12. (Currently Amended) A compound as claimed in ~~any of claims 1-11~~ claim 1, wherein Z is an optionally substituted N-linked 4 to 7 membered heterocycle~~, in particular optionally substituted piperidyl~~.

13. (Currently Amended) A compound as claimed in claim 1 having the formula (Ia):



(Ia)

wherein R_1, p, R_2, X, Y, Z, are as defined in ~~any of claims 1-12~~ claim 1 and A_1 is $-CH_2-$ or -HC(Me)-.

14. (Currently Amended) A compound as claimed in claim 1, which is

2-[4-Methoxy-3-(2-piperidin-1-yl-ethoxy)phenyl]-2,3-dihydroisoindol-1-one;
6-Fluoro-2-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)phenyl]-2,3-dihydroisoindol-1-one;
7-Bromo-2-{4-methoxy-3-[2-(4-methyl-piperidin-1-yl)-ethoxy]phenyl}-2,3-dihydroisoindol-1-one hydrochloride;
7-Chloro-2-{4-methoxy-3-[2-(4-methyl-piperidin-1-yl)-ethoxy]phenyl}-3-methyl-2,3-dihydroisoindol-1-one;
2-{4-Methoxy-3-[2-(4-methyl-piperidin-1-yl)-ethoxy]phenyl}-7-trifluoromethyl-2,3-dihydroisoindol-1-one;
5,7-Dichloro-2-{4-methoxy-3-[2-(4-methyl-piperidin-1-yl)-ethoxy]phenyl}-2,3-dihydroisoindol-1-one;
7-Chloro-2-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)phenyl]-2,3-dihydroisoindol-1-one;
6-Chloro-2-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)phenyl]-2,3-dihydroisoindol-1-one hydrochloride;
5-Chloro-2-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)phenyl]-2,3-dihydroisoindol-1-one;
5,7-Dichloro-2-{4-methoxy-3-[2-(*cis*-2,6-dimethyl-piperidin-1-yl)-ethoxy]phenyl}-2,3-dihydroisoindol-1-one 7-Chloro-2-{4-methoxy-3-[2-(4-methyl-piperidin-1-yl)-ethoxy]phenyl}-2,3-dihydroisoindol-1-one;
6-Chloro-2-{4-methoxy-3-[2-(4-methyl-piperidin-1-yl)-ethoxy]phenyl}-2,3-dihydroisoindol-1-one;
5-Chloro-2-{4-methoxy-3-[2-(4-methyl-piperidin-1-yl)-ethoxy]phenyl}-2,3-dihydroisoindol-1-one;
7-Methyl-2-{4-methoxy-3-[2-(4-methyl-piperidin-1-yl)-ethoxy]phenyl}-2,3-dihydroisoindol-1-one;
6,7-Difluoro-2-{4-methoxy-3-[2-(4-methyl-piperidin-1-yl)-ethoxy]phenyl}-2,3-dihydroisoindol-1-one;
5,6-Dichloro-2-{4-methoxy-3-[2-(4-methyl-piperidin-1-yl)-ethoxy]phenyl}-2,3-dihydroisoindol-1-one;
7-Fluoro-2-{4-methoxy-3-[2-(piperidin-1-yl)-ethoxy]phenyl}-2,3-dihydroisoindol-1-one;
4-Fluoro-2-{4-methoxy-3-[2-(piperidin-1-yl)-ethoxy]phenyl}-2,3-dihydroisoindol-1-one;

5,7-Dimethyl-2-{4-methoxy-3-[2-(4-methyl-piperidin-1-yl)-ethoxy]phenyl}-2,3-dihydroisoindol-1-one 6,7-Dichloro-2-{4-methoxy-3-[2-(4-methyl-piperidin-1-yl)-ethoxy]phenyl}-2,3-dihydroisoindol-1-one;

5-Fluoro-2-{4-methoxy-3-[2-(4-methyl-piperidin-1-yl)-ethoxy]phenyl}-7-trifluoromethyl-2,3-dihydroisoindol-1-one;
7-Chloro-4,5-difluoro-2-{4-methoxy-3-[2-(4-methyl-piperidin-1-yl)-ethoxy]phenyl}-2,3-dihydroisoindol-1-one;
4-Fluoro-2-{4-methoxy-3-[2-(4-methyl-piperidin-1-yl)-ethoxy]phenyl}- 7-trifluoromethyl-2,3-dihydroisoindol-1-one;
4-Fluoro-2-{4-methoxy-3-[2-(4-methyl-piperidin-1-yl)-ethoxy]phenyl}- 7-trifluoromethyl-2,3-dihydroisoindol-1-one;
4-Fluoro-2-{4-methoxy-3-[2-(4-methyl-piperidin-1-yl)-ethoxy]phenyl}- 7-trifluoromethyl-2,3-dihydroisoindol-1-one;
4-Fluoro-2-{4-methoxy-3-[2-(4-methyl-piperidin-1-yl)-ethoxy]phenyl}- 7-trifluoromethyl-2,3-dihydroisoindol-1-one;
5,7-Dichloro-2-{4-methoxy-3-[2-(4,4-dimethyl-piperidin-1-yl)-ethoxy]phenyl}-2,3-dihydroisoindol-1-one 5,7-Dichloro-2-{4-methoxy-3-[2-(azepan-1-yl)-ethoxy]phenyl}-2,3-dihydroisoindol-1-one;
5,7-Dichloro-2-{4-methoxy-3-[2-(2-methyl-piperidin-1-yl)-ethoxy]phenyl}-2,3-dihydroisoindol-1-one;
6-{4-Methoxy-3-[2-(4-methyl-piperidin-1-yl)-ethoxy]-phenyl}-2-methyl-4-trifluoromethyl-6,7-dihydro-pyrrolo[3,4-*b*]pyridin-5-one; or
5,7-Dichloro-4-fluoro-2-{4-methoxy-3-[2-(4-methyl-piperidin-1-yl)-ethoxy]phenyl}-2,3-dihydroisoindol-1-one;
or a pharmaceutically acceptable salt thereof.

15. (Currently Amended) A process for the preparation of a compound as claimed in ~~any of claims 1-14~~ claim 1 or a pharmaceutically acceptable salt thereof, which process comprises:
(a) reacting a compound of formula (II):



(II)

wherein R_1, R_2, p, A, X, and Y are as defined for formula (I), and L is a leaving group, with a compound of formula (III):

Z-H
(III)

wherein Z is as defined for formula (I); or

(b) reacting a compound of formula (IV):



(IV)

wherein Rx is alkyl and LG is a suitable leaving group, with a compound of formula (V) or a corresponding salt:



(V)

or

(c) reacting a compound of formula (VI):



(VI)

with a compound of formula (V) in the presence of $AlMe_3$ or a similar oxophilic reagent followed by treatment of the resulting amide under dehydrating conditions, e.g. with PPh_3 and dialkylazadicarboxylate;
and thereafter, for either process (a), process (b) or process (c), optionally followed by:

- removing any protecting groups; and/or
- converting a compound of formula (I) into another compound of formula (I); and/or
- forming a pharmaceutically acceptable salt.

16. (Currently Amended) A pharmaceutical composition comprising a compound as defined in ~~any of claims 1-14~~ claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.

17. (Cancelled)

18. (Cancelled)

19. (Cancelled)

20. (Currently Amended) A method of treatment of a CNS disorder in mammals ~~including humans,~~ which comprises administering to the sufferer a therapeutically safe and effective amount of a compound as claimed in ~~any of claims 1-14~~ claim 1 or a pharmaceutically acceptable salt thereof.

21. (Original) A method as claimed in claim 20, wherein the CNS disorder is depression or anxiety.

22. (Cancelled)

23. (Cancelled)

24. (New) A compound as claimed in claim 1, wherein p is 1, 2 or 3 and R_1 is/are chloro or fluoro.

25. (New) A compound as claimed in claim 1, wherein p is 1, 2 or 3 and R_1 is/are methyl.

26. (New) A compound as claimed in claim 1, wherein R_2 is methoxy.

27. (New) A compound as claimed in claim 1, wherein Z is an optionally substituted piperidyl.